Comparision of plasma concentrations of different load regimes of teicoplanin in patients with osteomyelitis by liquid chromatography-mass spectrometry monitoring

Published on Nov. 17, 2023Total Views: 1050 times Total Downloads: 508 times Download Mobile

Author: Hui-Min YU ¹ Hui-Jie YUE ¹ Hong-Bo QIAN ¹ Yan-Jie ZHANG ² Zhi-Wei HE ²  Qing ZHOU ¹

Affiliation: 1. Department of Clinical Pharmacy, General Hospital of Eastern Theater Command of the PLA, Nanjing 210002, China 2. Department of Orthopedics, General Hospital of Eastern Theater Command of the PLA, Nanjing 210002, China

Keywords: Teicoplanin Loading regimen Trough concentration Therapeutic drug monitoring LC-MS/MS

DOI: 10.12173/j.issn.1008-049X.202209161

Reference: Hui-Min YU, Hui-Jie YUE, Hong-Bo QIAN, Yan-Jie ZHANG, Zhi-Wei HE, Qing ZHOU.Comparision of plasma concentrations of different load regimes of teicoplanin in patients with osteomyelitis by liquid chromatography-mass spectrometry monitoring[J].Zhongguo Yaoshi Zazhi,2023, 26(10):51-58.DOI: 10.12173/j.issn.1008-049X.202209161.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish and validate a liquid chromatography-mass spectrometry (LC-MS/MS) method for the detection of teicoplanin concentration in plasma, and to analyze the achievement of teicoplanin trough concentrations (C_min) in patients with osteomyelitis at different loading doses in General Hospital of Eastern Theater Command of the PLA.

Methods To establish an LC-MS/MS method for the determination of teicoplanin C_min and investigate the specificity, standard curve, precision and recovery, matrix effect and stability of the method. 43 patients with osteomyelitis treated with teicoplanin were divided into two groups according to the dosing regimen: test group A received three loading doses of 400 mg, q12h and test group B received six loading doses of 400 mg, q12h, along with multiple therapeutic drug monitoring (TDM). In both groups, samples were collected 30 min before the maintenance dose on day four to detect teicoplanin C_min values in patients and teicoplanin C_min targets were compared between two groups.

Results The standard curve equation of teicoplanin in plasma was Y=0.032 4X+0.000 886 (r=0.996 4), and the linear relationship was good within 0.20-50.00 μg·mL^-1; the accuracy of quality control samples was 94.71%-112.50%; the intra-day and inter-day RSDs were 3.17%-15.19%; the extraction recoveries were 81.22%-91.26%; and the matrix effect was 93.54%-119.78%. In clinical application, the mean C_min of teicoplanin after loading dose in test group A was (8.32±4.76) μg·mL^-1, and the proportion of C_min≥10 μg·mL^-1 was only 25.90%; the mean C_min of teicoplanin after loading dose in test group B was (19.58±7.78) μg·mL^-1, and C_min was≥10 μg·mL^-1 in all 16 patients. There was a significant difference in mean C_min between two groups (P<0.000 1).

Conclusion The LC-MS/MS method developed in this trial is suitable for routine TDM with teicoplanin. In clinical practice, teicoplanin C_min compliance was poor with low-frequency loading regimens, while teicoplanin C_min compliance was superior with TDM-guided high-frequency loading regimens. Studies have shown the importance of teicoplanin TDM, particularly in patients at high risk of infection.

Full-text

Please download the PDF version to read the full text: download

References

1.Wilson AP. Clinical pharmacokinetics of teicoplanin[J]. Clin Pharmacokinet, 2000, 39(3): 167-183. DOI: 10.2165/00003088-200039030-00001.

2.Roberts JA, Stove V, De Waele JJ, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study[J]. Int J Antimicrob Agents, 2014, 43: 423-430. DOI: 10.1016/j.ijantimicag.2014.01.023.

3.沈琮, 陈文倩, 张相林. 替考拉宁治疗药物监测进展[J]. 中国医院用药评价与分析, 2019, 19(7): 890-894. [Shen C, Chen WQ, Zhang XL. Progress of therapeutic drug monitoring on teicoplanin[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2019, 19(7): 890-894.] DOI: 10.14009/j.issn.1672-2124.2019.07.037.

4.Menichetti F, Del Favero A. The role of gram-positive therapy in the neutropenic patient[J]. J Antimicrob Chemother, 1991, 27: 51-60. DOI: 10.1093/jac/27.suppl_b.51.

5.Ueda T, Takesue Y, Nakajima K, et al. Highdose regimen to achieve novel target trough concentration in teicoplanin[J]. J Infect Chemother, 2014, 20: 43-47.DOI: 10.1016/j.jiac.2013.08.006.

6.Wang XX, Jin PF, Li PM, et al. Interlaboratory analysis of teicoplanin plasma concentration assays among Chinese laboratories[J]. J Clin Pharm Ther, 2020, 45(5): 983-990.DOI: 10.1111/jcpt.13115.

7.吕碧君, 梁峰华, 谢慧, 等. 替考拉宁在重症肺炎患者中血药浓度监测与应用分析[J]. 中国医院药学杂志, 2017, 37(21): 2167-2172. [Lyu BJ, Liang FH, Xie H, et al. Serum concentration monitoring and application analysis of teicoplanin in patients with severe pneumonia[J]. Chinese Journal of Hospital Pharmacy, 2017, 37(21): 2167-2172.]DOI: 10.13286/j.cnki.chinhosppharmacyj.2017.21.14.

8.王曦培, 何国东, 郑志杰, 等. 高校液相色谱-质谱联用法检测患者血浆中替考拉宁的浓度[J]. 中国医院药学杂志, 2020, 40(15): 1616-1621. [Wang XP, He GD, Zheng ZJ, et al. Determination of teicoplanin in the patients plasma by high performance liquid chromatographymass spectrometry[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(15): 1616-1621.] DOI: 10.13286/j.1001-5213.2020.15.04.

9.Mouzopoulos G, Kanakaris NK, Kontakis G, et al. Management of bone infections in adults: the surgeon's and microbiologist's perspectives[J]. Injury, 2011, 42: 18-23. DOI: 10.1016/S0020-1383(11)70128-0.

10.时正媛, 庄健美, 顾红燕, 等. 超高效液相色谱法快速测定人血浆中替考拉宁的浓度及其应用[J]. 中国药学杂志, 2019, 54(6): 484-488. [Shi ZY, Zhuang JM, Gu HY, et al. Rapid determination of teicoplanin concentration in human plasma by UPLC and its application[J]. Chinese Pharmaceutical Journal, 2019, 54(6): 484-488.] DOI: CNKI:SUN:ZGYX.0.2019-06-009.

11.Chae H, Lee JJ, Cha K, et al. Measurement of teicoplanin concentration with liquid chromatography-tandem mass spectrometry method demonstrates the usefulness of therapeutic drug monitoring in hematologic patient populations[J]. Ther Drug Monit, 2018, 40(3): 330-336.DOI: 10.1097/FTD.0000000000000498.

12.Ueda T, Takesue Y, Nakajima K, et al. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg·mL-1 using a regimen of 12 mg·kg-1 for five doses within the initial 3 days[J]. BMC Pharmacol Toxico, 2020, 21(1): 1-10. DOI: 10.1186/s40360-020-00424-3.

13.Hagihara M, Umemura T, Kimura M, et al. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin resistant Staphylococcus aureus[J]. J Infect Chemother, 2012, 18(1): 10-16. DOI: 10.1007/s10156-011-0272-8.

14.Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. J Antimicrob Chemother, 2022, 77(4): 869-879. DOI: 10.1093/jac/dkab499.

15.中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6): 409-446. DOI: 10.3760/cma.j.issn.1001-0939.2018.06.004.

16.Pea F. Teicoplanin and therapeutic drug monitoring: an update for optimaluse in different patient populations[J]. J Infect Chemother, 2020, 26(9): 900-907. DOI: 10.1016/j.jiac.2020.06.006.

17.Nah SH, Im JH, Yeo JY, et al. Therapeutic drug concentrations of teicoplanin in clinical settings[J]. Infect Chemother, 2014, 46: 35-41. DOI: 10.3947/ic.2014.46.1. 35.

18.祖育娜, 张华, 周丽娟, 等. 不同剂量替考拉宁治疗老年重症革兰阳性菌感染患者的治疗药物浓度监测与疗效评估[J]. 中华医院感染学杂志, 2016, 26(23): 5379-5881. [Zu YN, Zhang H, Zhou LJ, et al. Monitoring of drugconcentrations of elderly patients with severegram-positive bacteria infections treated with differentdosagesof teicoplanin and assessment of cyrative effect[J]. Chinese Journal of Nosocomiology, 2016, 26(23): 5379-5881.] DOI: 10.11816/cn.ni.2016-161735.